TABLE 3.
Primary outcome measures of the two groups.
| FO group |
Placebo group |
Adjusted difference of FO vs. placebo | pa | |||
| Baseline | 12 week | Baseline | 12 week | |||
| Intention to treat (n = 54) | ||||||
| 60°/s knee extension peak TQ (R), Nm | 70.8 ± 26.9 | 78.4 ± 26.2 | 72.8 ± 29.2 | 80.5 ± 35.4 | −4.66 (−23.99, 13.97) | 0.593 |
| 60°/s knee extension peak TQ (L), Nm | 72.8 ± 23.7 | 79.6 ± 25.0 | 75.1 ± 27.1 | 83.1 ± 37.3 | −8.45 (−26.31, 9.41) | 0.400 |
| 60°/s knee flexion peak TQ (R), Nm | 23.1 ± 11.0 | 31.0 ± 12.7b | 26.8 ± 15.4 | 30.8 ± 16.0 | 3.08 (−7.14, 13.31) | 0.630 |
| 60°/s knee flexion peak TQ (L), Nm | 25.2 ± 9.2 | 29.4 ± 13.5 | 28.9 ± 13.3 | 28.3 ± 17.2 | 4.25 (−6.10, 14.59) | 0.437 |
| Per protocol (n = 49) | ||||||
| 60°/s knee extension peak TQ (R), Nm | 70.9 ± 27.5 | 80.1 ± 21.5 | 73.6 ± 31.0 | 81.5 ± 30.1c | −4.11 (−16.95, 8.74) | 0.671 |
| 60°/s knee extension peak TQ (L), Nm | 72.3 ± 24.0 | 79.9 ± 22.6c | 76.7 ± 28.4 | 84.4 ± 29.2c | −7.71 (−18.36, 2.94) | 0.823 |
| 60°/s knee flexion peak TQ (R), Nm | 22.9 ± 11.1 | 31.8 ± 11.7b | 26.8 ± 16.7 | 30.1 ± 13.7 | 4.26 (−4.25, 12.77) | 0.319 |
| 60°/s knee flexion peak TQ (L), Nm | 24.6 ± 8.9 | 30.1 ± 11.8c | 29.3 ± 14.0 | 27.9 ± 13.7 | 5.20 (−3.82, 14.22) | 0.252 |
Values are mean ± SD or mean (95% CI) unless otherwise indicated. FO, Fermented Oyster Extract; TQ, torque. aANCOVA adjusted for age, sex, and each baseline value over the 12-wk period. bP < 0.005, cP < 0.05 by paired t-test or Wilcoxon signed-rank test within each group.